Article

Genaera drops plan for wet AMD drug

Plymouth Meeting, PA-Genaera Corp. has decided to terminate its clinical development program for squalamine lactate (Evizon) for the treatment of wet age-related macular degeneration (AMD) after a comprehensive review of its portfolio and market conditions.

Plymouth Meeting, PA-Genaera Corp. has decided to terminate its clinical development program for squalamine lactate (Evizon) for the treatment of wet age-related macular degeneration (AMD) after a comprehensive review of its portfolio and market conditions.

The company plans to lay off about 30% of its workforce.

It had been pursuing a multi-center, randomized, open-label phase II study of squalamine lactate. Rapid acceptance of new and off-label products that improve vision in wet AMD significantly curtailed the rate of subject enrollment in the study, however, the company said.

The company plans to focus instead on development of trodusquemine for the treatment of obesity.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.